Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EPS (Weighted Average and Diluted)Shares Outstanding (Weighted Average)
Others
Ratios

China SXT Pharmaceuticals (SXTC) Restructuring Costs: 2020-2025

Historic Restructuring Costs for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Mar 2025 value amounting to $379,997.

  • China SXT Pharmaceuticals' Restructuring Costs was N/A to $164.1 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $164.1 billion, marking a year-over-year change of. This contributed to the annual value of $379,997 for FY2025, which is 26.85% up from last year.
  • China SXT Pharmaceuticals' Restructuring Costs amounted to $379,997 in FY2025, which was up 26.85% from $299,564 recorded in FY2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Restructuring Costs peaked at $180.4 billion during FY2021, and registered a low of $299,564 during FY2024.
  • For the 3-year period, China SXT Pharmaceuticals' Restructuring Costs averaged around $384,632, with its median value being $379,997 (2025).
  • Per our database at Business Quant, China SXT Pharmaceuticals' Restructuring Costs plummeted by 100.00% in 2022 and then grew by 26.85% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Restructuring Costs (Yearly) stood at $180.4 billion in 2021, then plummeted by 100.00% to $579,774 in 2022, then fell by 18.19% to $474,334 in 2023, then plummeted by 36.85% to $299,564 in 2024, then grew by 26.85% to $379,997 in 2025.